Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Next Previous
Trial Profile

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 12 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Vemurafenib (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms B-FAST
  • Sponsors Roche

    • Most Recent Events

    • 08 Apr 2024 Planned End Date changed from 27 Apr 2024 to 3 Aug 2028.
    • 08 Apr 2024 Planned primary completion date changed from 27 Apr 2024 to 3 Aug 2028.
    • 24 Oct 2023 Results (n=87) of updated data with longer follow-up, and exploratory correlative ctDNA and biomarker analyses from sub-groups of cohort A presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top